BEAM

Beam Therapeutics Inc.

Price

$29.07

return (12m)

77.80%

p/e

-32.03

p/bv

2.56

DIVIDEND YIELD

0.00%

BEAM price

Beam Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment BEAM

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

8.11%

3 months

5.06%

1 year

77.80%

2 years

16.28%

5 years

-71.49%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals BEAM

Valuation

P/E

-32.03

Sector -4.38

Industry -4.38

P/BV

2.56

Sector 2.02

Industry 2.02

P/Revenue (PSR)

17.54

Sector -4.40

Industry -4.40

EV/EBITDA

-13.90

Sector -263.09

Industry -263.09

EV/EBIT

-13.30

Sector -702.90

Industry -702.90

P/EBITDA

-7.69

Sector -4.39

Industry -4.39

P/EBIT

-7.24

Sector -4.73

Industry -4.73

P/Total Assets

1.97

Sector 1.49

Industry 1.49

P/Net Current Assets

3.18

Sector -11.70

Industry -11.70

P/Working Capital

2.49

Sector -3.19

Industry -3.19

EPS

-0.82

Sector -2.14

Industry -2.14

BVPS

10.26

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-24,722.45%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-25,826.53%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-54.75%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-8.00%

Sector -65.14%

Industry -65.14%

ROA

-6.16%

Sector -65.53%

Industry -65.53%

ROIC

-197.42%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

14.57

Sector 2.90

Industry 2.90

Net Debt / EBITDA

8.69

Sector -6.07

Industry -6.07

Net Debt / EBIT

8.32

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.99

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.09

Sector -0.05

Industry -0.05

Equity/Assets

0.77

Sector 0.41

Industry 0.41

Liabilities/Assets

0.23

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

24.65%

Sector -

Industry -

5Y Earnings CAGR

-25.44%

Sector -

Industry -

Fundamentals BEAM

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BEAM Beam Therapeutics Inc.	$29.07	70.00%	0.00%	-32.03	2.56	-8.00%	-54.75%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BEAM Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Beam Therapeutics

Beam Therapeutics Inc.

Average Investor10 user rating

4.0 (2 people)

United States

9 years

Founded: 2017

2020

Time since IPO - 6 years

181

Employees

Beam Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.74 billion, with shareholders equity totaling $1.07 billion.

The company employs approximately 181 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Beam Therapeutics Inc. reported $156.04 million in revenue, generating net income of $-85.43 million.

Key financial metrics include a P/E ratio of -32.03, a price-to-book (P/B) ratio of 2.56, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BEAM.

Market cap

$2.74 billion

Net worth

$1.07 billion

$1,067,440,000.00

Assets

$1.39 billion

$1,386,360,000.00

Total Shares Outstanding

104.00 million

104,000,000

Average Daily Trading Volume

$2.25 million

$2,245,028.00

Sector

Health Care

Industry

Biotechnology

BEAM

BEAM revenue and profits

Financial Results BEAM

DRAG THE FRAME TO SEE MORE DATA

BEAM cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Beam Therapeutics (BEAM) today?

A cotação de Beam Therapeutics (BEAM) hoje está em US$ 29.07, com uma variação de 77.8% em relação ao último ano. A cotação de Beam Therapeutics (BEAM) iniciou o ano negociando na casa dos US$ 27.72 e hoje está em US$ 29.07. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Beam Therapeutics (BEAM) e dados de ações do Ibovespa e mercados internacionais.

Quando Beam Therapeutics (BEAM) paga dividendos?

Beam Therapeutics (BEAM) não distribuiu dividendos no último ano.

Is Beam Therapeutics (BEAM) a good investment?

Atualmente, Beam Therapeutics (BEAM) está cotada a US$ 29.07, com um P/L de -32.03, representando um desvio de -2,003% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 77.8 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 77.80%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Beam Therapeutics (BEAM) stock?

Investir em ações de Beam Therapeutics (BEAM) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Beam Therapeutics (BEAM) yield today?

A rentabilidade de Beam Therapeutics (BEAM) foi de 8.11% no último mês, 77.80% no último ano e -71.49% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Beam Therapeutics (BEAM) hoje, o investimento total seria de US$ 2,907.00, com base na cotação atual de US$ 29.07.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 5,168.65
Em 5 anos: US$ 828.79
Em 10 anos: US$ 2,907.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

BEAM

Beam Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BEAM

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING BEAM WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Beam Therapeutics

Beam Therapeutics Inc.

United States

9 years

2020

181

PROFIT X PRICE BEAM

Financial Results BEAM

BEAM cash flow

Asset, Revenue and Profit Growth - BEAM

BEAM balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions